News About: Pharm. Industry
Sanofi appoints CEOs for Consumer Healthcare and Diabetes & Circulatory Divisions
On the 28th, Sanofi-Aventis Korea(CEO Kyung-Eun Bae), a pharmaceutical business division of the global healthcare company Sanofi, announced appointment of the former Boehringer Ingelheim Korea Consumer Healthcare Divi...
KPBMA completes personnel appointment
The Korea Pharmaceutical and Bio-Pharma Manufacturers Association(Chairman Hee-Mok Won, KPBMA) held the 6th Chairmen’s Meeting on the 28th and decided the agenda of chairmen appointment for the association’s committee...
Listed pharmas’ operating profit ratio dropped in KOSPI, but increased in KOSDAQ
Last year, the KOSPI listed pharmaceutical companies’ average operating profit ratio was significantly decreased, but the one of KOSDAQ listed pharmaceutical companies was increased by more than 10%.
According to the...
BAI’s inspection result on MOHW this April
Whien it comes to Hanmi Pharm’s concealment of side effect and delayed notice about the ‘Olita Tab’ clinical trial, the Board of Audit and Inspection of Korea(BAI) will reveal the inspection result on the Ministry of ...
Santen Pharmaceutical Korea appoints VP Han-Woong Lee as new CEO
Santen Pharmaceutical Korea announced on the 27th that it promoted Vice President Han-Woong Lee, Head-Pharmaceutical Business, to President and appointed him as a new CEO from the 1st of April.
Vice President Han-Woo...
Kuhnil & Daiichi Sankyo’s joint sales of dyslipidemia treatment ‘Mevalotin’
For ‘Mevalotin(generic name: pravastatin),’ the dyslipidemia treatment, Kuhnil Pharm(CEO Young-Joong Kim) and Daiichi Sankyo Korea(CEO Dae-Joong Kim) will started the joint sales from the 1st of April.
Daiichi Sankyo...
Listed pharmas own approx. KRW 9 trillion surpluses, Yuhan has the most
It was observed listed pharmaceutical companies owns KRW 8.9 trillion surpluses, and Yuhan Corporation owns the highest amount, KRW 1.4112 trillion among the companies.
According to the Yakup Shinmoon’s(www.yakup.com...
Listed pharmas getting better with cash flow
It was researched listed pharmaceutical companies had 35% increased cash flow for operating activities.
According to the Yakup Shinmoon’s(www.yakup.com) analysis result of listed pharmaceutical companies’ 2016 audit ...
KOSDAQ pharmas superior to KOSPI ones in SG&A expenses growth rate
Last year, KOSDAQ listed pharmaceutical companies had a higher increase of SG&A(selling, general and administrative) expenses than the KOSPI listed pharmaceutical companies’ increase on average. In the 4th quarter aft...
Listed pharmas took 69 days for inventory asset rotation period
It was analyzed it took 69 days – it was increased by 3.7 days compared to the year before – on average to clear out the stock in 2016.
According to the Yakup Shinmoon’s(www.yakup.com) analysis result of KOSPI and KO...
